Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Eliminating Platinum Chemotherapy-induced Peripheral Neuropathy through Subcellular Targeting of a Platinum Drug

FY 2013-14

Summary
Despite advances in cancer therapy made in recent decades, chemotherapy remains the only treatment option against some of the most common cancers. The efficacy of these treatments is limited by varied and severe side effects. One of the most common of these effects is the development of severe pain and sensitivity in the extremities, known as peripheral neuropathy. It is known that this effect emerges because chemotherapies are particularly toxic to nerve cells, but the reason why is unclear. Some evidence suggests that chemotherapeutic drugs damage cellular compartments called mitochondria. These structures are the powerhouses of neuronal cells, providing the chemical energy that allows them to function normally. Our group specializes in making modified chemotherapeutics that can be selectively targeted to different places within the cell. We propose to modify an anticancer drug so that it is effectively excluded from mitochondria. We will then test whether targeting a drug in this way can reduce chemotherapy's neurotoxic effects. We hope that by guiding chemotherapy away from an undesired cellular locale we can eliminate a terrible condition that afflicts thousands of Canadian cancer patients each year.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
299913
Name
Wisnovsky Simon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Eliminating Platinum Chemotherapy-induced Peripheral Neuropathy through Subcellular Targeting of a Platinum Drug
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chemotherapy; Cisplatin; Mitochondria; Peptide Chemistry; Peripheral Neuropathy
Abstract
Despite advances in cancer therapy made in recent decades, chemotherapy remains the only treatment option against some of the most common cancers. The efficacy of these treatments is limited by varied and severe side effects. One of the most common of these effects is the development of severe pain and sensitivity in the extremities, known as peripheral neuropathy. It is known that this effect emerges because chemotherapies are particularly toxic to nerve cells, but the reason why is unclear. Some evidence suggests that chemotherapeutic drugs damage cellular compartments called mitochondria. These structures are the powerhouses of neuronal cells, providing the chemical energy that allows them to function normally. Our group specializes in making modified chemotherapeutics that can be selectively targeted to different places within the cell. We propose to modify an anticancer drug so that it is effectively excluded from mitochondria. We will then test whether targeting a drug in this way can reduce chemotherapy's neurotoxic effects. We hope that by guiding chemotherapy away from an undesired cellular locale we can eliminate a terrible condition that afflicts thousands of Canadian cancer patients each year.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wisnovsky, Simon
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2013-14) | Canada Spends